Skip to main content
. 2022 Oct 6;38(5):1260–1270. doi: 10.1093/ndt/gfac280

Figure 6:

Figure 6:

Cumulative incidence of abrupt declines in kidney function per 1000 patients treated with placebo versus dapagliflozin, in addition to standard therapy, over a 10-year horizon.